The Effects of Inspiratory Muscle Training in Patients With Heart Failure and Obstructive Sleep Apnea Syndrome
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Carine C Callegaro, PhD
- Phone Number: 55 55 9914-6712
- Email: ccallegaro@unicruz.edu.br
Study Locations
-
-
Rio Grande do Sul
-
Cruz Alta, Rio Grande do Sul, Brazil, 9800050
- Recruiting
- University of Cruz Alta
-
Contact:
- Carine C Callegaro
- Email: ccallegaro@unicruz.edu.br
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Heart failure patients with obstructive sleep apnea- hypopnea
- Heart failure patients without sleep apnea
- Left ventricle fraction ejection < 51 % for men and < 53% for woman
- Must be clinically stable
- New York Heart Association I, II and III
- Without changes in medication for the last three months.
Exclusion Criteria:
- Unstable angina
- Atrial fibrillation
- Acute myocardial infarction (<6 months)
- Recent heart surgery (<6 months)
- Chronic metabolic disease
- Infectious disease
- Anemia
- Severe hypoxemia
- Neuromuscular disease
- Diabetes mellitus
- Obesity
- Use of continuous positive airway pressure
- Smoking
- Pulmonary disease (forced vital capacity <80% of predicted and / or forced expiratory volume in one second <70% predicted).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Inspiratory muscle training (IMT)
Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 30% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 minutes for 12 weeks.
During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min.
Inspiratory load will be set at 30% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 30% of MIP.
Each week, six training sessions will be held at home and a training session will be supervised in the research center.
|
Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 30% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 minutes for 12 weeks.
During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min.
Inspiratory load will be set at 30% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 30% of MIP.
Each week, six training sessions will be held at home and a training session will be supervised in the research center.
|
|
Placebo Comparator: Sham IMT
Participants will be submitted to inspiratory muscle training with the same equipment as the intervention group, but without a load generating resistance.
Sham IMT Participants will receive IMT for 30 min, 7 times per week for 12 weeks using Inspiratory muscle trainer device (PowerBreathe).
During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance.
Each week, six training sessions will be held at home and a training session will be supervised in the research center.
|
Participants will be submitted to inspiratory muscle training with the same equipment as the intervention group, but without a load generating resistance.
Sham IMT Participants will receive IMT for 30 min, 7 times per week for 12 weeks using Inspiratory muscle trainer device (PowerBreathe).
During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance.
Each week, six training sessions will be held at home and a training session will be supervised in the research center
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Apnea hypopnea index
Time Frame: 12 weeks
|
measured by portable polysomnography [in events/hour]
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
sleepiness
Time Frame: 12 weeks
|
measured by Epworth Sleepiness Scale [in score]
|
12 weeks
|
|
sleep quality
Time Frame: 12 weeks
|
assessed by the Pittsburgh sleep quality index [in score]
|
12 weeks
|
|
cognitive function
Time Frame: 12 weeks
|
measured by the mini-mental state [in points]
|
12 weeks
|
|
motor task
Time Frame: 12 weeks
|
assessed by the execution of a sequence of digital movements [in time required and number of execution errors]
|
12 weeks
|
|
executive function measured by Trail Making Test
Time Frame: 12 weeks
|
measured by Trail Making Test.
In Part A, participants are asked to link numbered points randomly distributed on a sheet of paper in ascending order according to numbers.
In Part B, the participants are asked to link numbers and letters alternately [in time of test performance, counts the number of errors, and calculates the difference in times: B-A.].
|
12 weeks
|
|
quality of life assessed by the The Medical Outcomes Study - Short-form 36 (SF-36)
Time Frame: 12 weeks
|
assessed by the The Medical Outcomes Study - Short-form 36 (SF-36)
|
12 weeks
|
|
peak oxygen consumption
Time Frame: 12 weeks
|
It will be assessed using of treadmill stress test with Bruce protocol.
The peak oxygen consumption will be estimated according to the method established by the American College Sports Medicine [in mL.kg-1.min-1]
|
12 weeks
|
|
chemoreflex sensitivity
Time Frame: 12 weeks
|
peripheral chemoreflex will be assessed by transient hypoxia [in L.min-1.mmHg] and central chemoreflex by hypercapnic hyperoxic in [L.
min-1.
%SatO2]
|
12 weeks
|
|
vagal modulation measured by heart rate monitoring in the time domain (spectral analysis)
Time Frame: 12 weeks
|
measured by heart rate monitoring in the time domain by spectral analysis [in normalized units]
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Carine C Callegaro, PhD, University of Cruz Alta
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CAAE: 25471413.7.0000.5322
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.